TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03071588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical rotary burs
Description: A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carisolv gel
Description: A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
Study: NCT00402948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: 0.25mg, 0.5mg for 14 days, daily dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM8
Description: inhalation 0.25mg daily for 14 days
Study: NCT02392637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT00260533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Flexible dose, up to 50 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (matching to atomoxetine)
Study: NCT02631239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1g/m2/d IV \*1d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200mg/d PO \*3d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 200mg/d PO \*3d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg/d PO \*3d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg/d PO \*3d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/m2/d IM \*1d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: 2500IU/m2/d IM \*1d
Study: NCT00775320

Intervention type: PROCEDURE
Intervention: FLT-PET scan
Description: Imaging test
Study: NCT03797261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral
Study: NCT02631239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50-56Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 50-56Gy
Study: NCT03797261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: solution, intravenous
Study: NCT02423928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell based cryoimmunotherapy
Description: Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
Study: NCT00040677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose ICA-17043
Description: Low dose arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ICA-17043
Description: 150 mg Loading Dose; 10 mg daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
Study: NCT03889496

Intervention type: RADIATION
Group type: OTHER
Intervention: indium-111-exendin SPECT/CT
Description: SPECT/CT imaging after injection with In-111-DTPA-exendin-4
Study: NCT02789254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLYSYN
Description: Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA\* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~\* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.
Study: NCT02824666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-9242
Description: Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-9242
Description: Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]Fallypride Imaging
Description: Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]Fallypride Imaging
Description: Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].
Study: NCT02941250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISSD emulator
Description: induced tachy-arrhythmia to be terminated by ISSD emulator
Study: NCT00645801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lubiprostone (Amitiza)
Description: 24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amitiza Placebo
Study: NCT00716508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair with transpatellar tunnels
Description: Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair with suture anchors.
Description: Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
Study: NCT01544829

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theobromine
Description: Single dose of theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theobromine
Description: Multiple doses of theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT03546322

Intervention type: OTHER
Intervention: Registry
Description: Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
Study: NCT03173573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for FDL176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for FDL176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for FDL176
Study: NCT04698642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: Both sides of the abdominal region will receive CBL-514.
Study: NCT01605292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: Manual palpation for localizing radial artery for inserting needle.
Study: NCT01408173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-11 for intravenous or oral administration.
Description: NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
Study: NCT00665652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
Study: NCT03505502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tranexamic acid
Description: in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
Study: NCT04464954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular semi-permanent (ASP gold) needles
Description: ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal (long) needles using J-type No. 2 (.18)x 15mm
Description: Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pyonex needles (Seirin Yellow 0.2 x 0.6mm)
Description: Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
Study: NCT03505502

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV tranexamic acid
Description: in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV tranexamic acid
Description: in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
Study: NCT03542877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tablet: Cabozantinib
Description: Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
Study: NCT02660151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper-CL™ lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper-CL™ lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regular soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regular soft contact lens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salt solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salt solution
Study: NCT01394796

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active treatment is given.
Study: NCT01424384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Neurophysiological testing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK424887
Description: Neurophysiological testing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plactebo To Match
Description: Neurophysiological testing
Study: NCT02195102

Intervention type: DEVICE
Intervention: Transcatheter aortic valve Replacement
Study: NCT04017663

Intervention type: OTHER
Intervention: Application of questionnaires
Description: Application of questionnaires to identify characteristics and main barriers of patients

Intervention type: OTHER
Intervention: Application of questionnaires
Description: Application of questionnaires to identify characteristics and main barriers of patients
Study: NCT03466814

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT04337645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment of peri-implantitis
Description: resective surgical treatment of peri-implantitis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment of peri-implantitis
Description: resective surgical treatment of peri-implantitis
Study: NCT03516188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alginate-antacid group
Description: Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non antacid alginate group
Description: Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
Study: NCT02161016

Intervention type: DEVICE
Group type: OTHER
Intervention: map3
Description: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
Study: NCT00240513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100 mg capsules OD for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline plus tretinoin
Description: 100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
Study: NCT00994513

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: 1200 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1200 mg/day
Study: NCT00813202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
Study: NCT04051424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ConMed bite block
Description: Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConMed bite block
Description: Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McKay airway
Description: Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McKay airway
Description: Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Williams Airway
Description: Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Williams Airway
Description: Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
Study: NCT01730794

Intervention type: OTHER
Group type: OTHER
Intervention: NAVA ventilation
Description: Neurally adjusted ventilatory assist

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Lung Protective Ventilation
Description: conventional protective mechanical ventilation
Study: NCT02057978

Intervention type: PROCEDURE
Intervention: EXCEL DES implatation
Description: Implant DES for CAD cases
Study: NCT02558296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: 20 mg, tablet
Study: NCT02057978

Intervention type: PROCEDURE
Intervention: EXCEL-II DES implantation
Description: Implant DES for CAD cases
Study: NCT02502097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 50 mg tablet, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 50 mg tablet, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 50 mg tablet, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 50 mg tablet, administered by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to gefapixant, tablet administered by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to gefapixant, tablet administered by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to gefapixant, tablet administered by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to gefapixant, tablet administered by mouth
Study: NCT00203476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colestipol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Study: NCT02293148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 75 mg
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 500 mg
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Study: NCT02558296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg tablet to match active comparator
Study: NCT02266511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax®, Norman II facility

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax®, Norman II facility

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax®, Nishine facility

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax®, Nishine facility
Study: NCT03125395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: Participants received LUM/IVA every q12h.